Ultimovacs ASA (STU:7UM) Net Change in Cash : €-16.05 Mil (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Ultimovacs ASA Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Ultimovacs ASA's Net Change in Cash for the three months ended in Mar. 2024 was €-4.04 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2024 was €-16.05 Mil.

Ultimovacs ASA Net Change in Cash Historical Data

The historical data trend for Ultimovacs ASA's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ultimovacs ASA Net Change in Cash Chart

Ultimovacs ASA Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Change in Cash

Get a 7-Day Free Trial

28.33

3.90

13.13

-14.22

-13.80

Ultimovacs ASA Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Change in Cash	Get a 7-Day Free Trial															-1.75	-5.25	-3.83	-2.93	-4.04

Ultimovacs ASA Net Change in Cash Calculation

Ultimovacs ASA's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	-16.501	+	1.22	+	-0.161	+	1.642
	=	-13.80

Ultimovacs ASA's Net Change in Cash for the quarter that ended in Mar. 2024

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= -4.004 + 0.267 + -0.048 + -0.255

= -4.04

Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-16.05 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ultimovacs ASA Net Change in Cash Related Terms
Thank you for viewing the detailed overview of Ultimovacs ASA's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Ultimovacs ASA (STU:7UM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ultimovacs ASA (STU:7UM) » Definitions » Net Change in Cash

Comparable Companies

OSL:NYKD OSL:AZT OSL:HBC OSL:BGBIO OSL:CIRCA OSL:EXTX OSL:TRMED OSL:LYTIX OSL:ABS OSL:PCIB OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX

Traded in Other Exchanges

ULTIo:Sweden ULTI:Norway

Address

Ullernchausseen 64, Oslo, NOR, 0379

Website

https://www.ultimovacs.com

Ultimovacs ASA is a pharmaceutical company involved in developing novel immunotherapies against cancer. Its product candidate is UV1, a peptide-based vaccine inducing T cell responses against the universal cancer antigen telomerase. The company and its proprietary technology are based on preclinical and clinical research on immunotherapies conducted at the Oslo University Hospital.

Ultimovacs ASA (STU:7UM) Headlines

No Headlines